Related Experiment Videos
Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management
1Lawrence Berkeley Laboratory, Life Science Division, University of California, Berkeley.
Insights
Aggressive lipoprotein manipulation, including diet and medication, significantly improved coronary artery disease measurements and reduced cardiovascular events in clinical trials. This approach offers a cost-effective strategy for managing atherosclerosis.
Area of Science:
- Cardiology
- Preventive Medicine
- Clinical Trials
Background:
- Previous studies suggested coronary artery disease regression with lipoprotein manipulation but often lacked control groups and sufficient sample sizes.
- Existing research on atherosclerosis management requires robust evidence from controlled trials.
Purpose of the Study:
- To critically review and synthesize findings from randomized controlled trials on lipoprotein manipulation for coronary artery disease.
- To assess the impact of lipoprotein manipulation on atherosclerosis progression and regression using coronary arteriography.
Main Methods:
- Meta-analysis of ten randomized controlled clinical trials involving 2095 subjects.
- Coronary arteriography was used to assess atherosclerosis progression and regression rates.
- Studies included non-pharmacological approaches, single/multiple drug therapies combined with diet.
Main Results:
- Lipoprotein manipulation led to a significant reduction in disease progression (mean 23.6%) and an increase in regression (mean 20.0%) compared to controls.
- Achieved significant lipid profile improvements: 28% LDL cholesterol reduction, 11% triglyceride reduction, and 11% HDL cholesterol increase.
- Fewer clinical events were observed in treatment groups over 2-4 years, with manageable side effects.
Conclusions:
- Aggressive lipoprotein manipulation demonstrates convincing evidence for improved arteriographic measurements and reduced cardiovascular events within 2-4 years.
- This strategy is suggested to be cost-effective for managing coronary artery disease in the broader population.
- Directed lipoprotein manipulation offers a promising therapeutic avenue for reducing clinical events in patients with known coronary artery disease.
Background:
Numerous reports suggest that coronary artery disease can regress with lipoprotein manipulation. Many of these reports lack control groups and contain relatively small numbers.
Methods And Results:
Ten randomized controlled clinical trials using coronary arteriography to assess the effect of lipoprotein manipulation on the rate of progression and regression of atherosclerosis have been either published or reported as an abstract at a national meeting. These studies were critically reviewed for individual differences and combined clinically applicable lessons. These trials involved a total of 2095 subjects and have consistently reported reduction in the percentage of patients arteriographically defined as progressing (mean, 23.6%) and an increase in the percentage regressing (mean, 20.0%) compared with control groups. Compared with large clinical trials using clinical end points, lipoprotein change was greater, achieving on average a 28% reduction in low-density lipoprotein cholesterol, 11% reduction in triglycerides, and 11% increase in high-density lipoprotein cholesterol compared with control groups. Four investigations used a nonpharmacological approach, and seven used single and multiple drug therapy combined with diet. Despite the relatively brief treatment time of often 2 to 4 years, clinical events were fewer in the treatment groups; within some studies, this reached statistical significance. Side effects from the different therapies were tolerated by most patients, and severe adverse clinical events were few.
Conclusions:
These trials present convincing evidence that aggressive lipoprotein manipulation can result in improved arteriographic measurements and fewer cardiovascular events in a relatively short period of time of 2 to 4 years. Extrapolation of this information to the larger population with known coronary artery disease suggests that directed lipoprotein manipulation can reduce clinical events in a cost-effective manner.